The patent covers the following:
"Such potential applications include diseases with an inflammatory component namely, respiratory tract infections (RSV, SARS), neuroinflammation (WNV, HSV, CMV), liver infections (HCV), asthma, autoimmunity (MS, Lupus, liver disease, psoriasis, Crohn's Disease, Inflammatory bowel disease, etc.), atherosclerosis, angiogenesis and cancer (prostrate, breast, melanoma, gastric, colon, ovarian, etc.), fibrosis and transplant rejection and GvHD. Methods and compounds of the present invention may also be used in connection with transplantation including GvHD, autoimmunity (MS, Lupus, Psoriasis, autoimmune liver disease, etc.), inflammation in respiratory viral diseases (RSV, SARS), other viral diseases (HCV, CMV, WNV), infectious agents, cancer applications for angiogenesis and unlocking Treg suppression of antitumor CTLs, and atherosclerosis and fibrosis. As indicated here, the interaction between the CCL5 ligand and the CCR5 receptor is implicated in several disease states."
NSAIDS are written to reduce inflammation. When a doctor appreciates some form of inflammation, he might decide to write an NSAID like celebrex or meloxicam. However, there are forms of inflammation that NSAIDS do not address. Sometimes the synovial swelling that occurs in Rheumatoid conditions is so severe, that even DMARDs cannot reduce.
What about after a round of steroids, all of a sudden a patient finds themselves with another disease they never knew they had. Why is that? Because the prednisone reduced their immune system to allow a whole new disease to envelop them and they become inflammed. In such cases, it becomes a no brainer to bring in leronlimab to normalize the balance of T cells and CCR5 receptors which is what happens in long covid treated with leronlimab.
What implications could that point to? Immunosuppression is common in many disorders, especially cancer and diabetes. Especially those who require chemotherapy. Chemotherapy acts like a poison. What do you think that does to someone's immune system? Their entire immune system, both Innate and Adaptive are both probably dead from the chemo itself. All white blood cell lines fatigued to the point of exhaustion trying to fight off the chemo. How low do you think the CCR5 count is in chemo patients? Probably zero. Many elderly too are immunosuppressed. Somehow, they are unable to mount the appropriate response when they become infected. Could they have low CCR5 levels as they age? Diabetics who have difficulty with glucose control tend to be immunosuppressed. Could higher sugar levels have an effect on CCR5 surface expression? And what about those who require long stents of and large doses of prednisone and cortisone. Their immune systems are suppressed. Could cortisone itself interact with CCR5 and disable it? Many auto-immune patients see rheumatologists are prescribed cortisone and other anti-inflammatory medications, many of which are called DMARDs which are Disease Modifying Anti-Rheumatic Drugs. These medications suppress select portions of the immune system so the patient no longer suffers from diseases which attack the person him/herself, which are auto-immune disorders.
Convergence
"Such potential applications include diseases with an inflammatory component namely, respiratory tract infections (RSV, SARS), neuroinflammation (WNV, HSV, CMV), liver infections (HCV), asthma, autoimmunity (MS, Lupus, liver disease, psoriasis, Crohn's Disease, Inflammatory bowel disease, etc.), atherosclerosis, angiogenesis and cancer (prostrate, breast, melanoma, gastric, colon, ovarian, etc.), fibrosis and transplant rejection and GvHD. Methods and compounds of the present invention may also be used in connection with transplantation including GvHD, autoimmunity (MS, Lupus, Psoriasis, autoimmune liver disease, etc.), inflammation in respiratory viral diseases (RSV, SARS), other viral diseases (HCV, CMV, WNV), infectious agents, cancer applications for angiogenesis and unlocking Treg suppression of antitumor CTLs, and atherosclerosis and fibrosis. As indicated here, the interaction between the CCL5 ligand and the CCR5 receptor is implicated in several disease states."
NSAIDS are written to reduce inflammation. When a doctor appreciates some form of inflammation, he might decide to write an NSAID like celebrex or meloxicam. However, there are forms of inflammation that NSAIDS do not address. Sometimes the synovial swelling that occurs in Rheumatoid conditions is so severe, that even DMARDs cannot reduce.
What about after a round of steroids, all of a sudden a patient finds themselves with another disease they never knew they had. Why is that? Because the prednisone reduced their immune system to allow a whole new disease to envelop them and they become inflammed. In such cases, it becomes a no brainer to bring in leronlimab to normalize the balance of T cells and CCR5 receptors which is what happens in long covid treated with leronlimab.
What implications could that point to? Immunosuppression is common in many disorders, especially cancer and diabetes. Especially those who require chemotherapy. Chemotherapy acts like a poison. What do you think that does to someone's immune system? Their entire immune system, both Innate and Adaptive are both probably dead from the chemo itself. All white blood cell lines fatigued to the point of exhaustion trying to fight off the chemo. How low do you think the CCR5 count is in chemo patients? Probably zero. Many elderly too are immunosuppressed. Somehow, they are unable to mount the appropriate response when they become infected. Could they have low CCR5 levels as they age? Diabetics who have difficulty with glucose control tend to be immunosuppressed. Could higher sugar levels have an effect on CCR5 surface expression? And what about those who require long stents of and large doses of prednisone and cortisone. Their immune systems are suppressed. Could cortisone itself interact with CCR5 and disable it? Many auto-immune patients see rheumatologists are prescribed cortisone and other anti-inflammatory medications, many of which are called DMARDs which are Disease Modifying Anti-Rheumatic Drugs. These medications suppress select portions of the immune system so the patient no longer suffers from diseases which attack the person him/herself, which are auto-immune disorders.
Convergence
Quote:"I see this first partner as a BP who may be sort of "disliked" by the rest of the BP group. Maybe, their medications are running close to the end of patent. Maybe, their medications are not as functional as the latest and greatest. Maybe favor and chances have been given unfairly to other BP groups who have learned to play the bribery game.
Yet, it remains strong. It plans a Take over, by planning its bases.
It plans to Join, with the strategic alliances. To Join, with the waterfront areas. Leronlimab is the jack of all trades and it excels on each indication, exceedingly well. It is not just the master of one indication. It is the master of many an indication while also being the jack of them all. This BP who requires CytoDyn's courtship, pursues CytoDyn for the assistance that Leronlimab affords them in their plight to win success in their war against MASH, HIV, mTNBC and mColo-Rectal Cancer.
GSK has a new Chief Scientific Advisor Tony Wood who favors CCR5 antagonists as he has invented Maraviroc and he knows the power of the CCR5 antagonist mechanism of action.
My suspicion once Amarex arbitration settles is that Sidley Austin becomes CytoDyn's enforcement. The Partnerships that will be set up and enacted need to be delt with and controlled to prevent infiltrations. With an enforcer present, this will be kept at bay.
CytoDyn shall require an internal coordinator. Could our future include a non-Pharm entity like Sidley Austin? Sidley Austin currently are the premier attorneys in defense against fraudulent business practices. CytoDyn has the premier jack of all trades, master of many indication monoclonal antibody. There is a ton of news out there. You can find it yourself, as to what is happening to CytoDyn and Leronlimab. Because of Leronlimab's excellent diversity and usefulness, CytoDyn is and will continue to be pushed and pressured from all sides, to be able to maintain any form of presence in the Big Pharma world. Yet, this is exactly where CytoDyn belongs, as the premier play in HIV, NASH and oncology with the use of this brilliant CCR5 blockade. The two companies could help each other out big time if they would play their cards right. This has to play itself out, and I have my fingers crossed, but am skeptical."
5
